Conference Coverage

Staging System Classifies Nearly All Patients With Lewy Body Synucleinopathy

The system can categorize patients, regardless of their specific synucleinopathies.


 

LOS ANGELES—The Unified Staging System for Lewy Body Disorders (USSLB) enables the categorization of almost all brains with Lewy body synucleinopathy, according to research described at the 70th Annual Meeting of the American Academy of Neurology. The USSLB’s stages correlate significantly with motor and nonmotor findings. “Wider use of the USSLB would help standardize research in synucleinopathies,” said Charles H. Adler, MD, PhD, Professor of Neurology at Mayo Clinic in Scottsdale, Arizona.

Charles H. Adler, MD, PhD

Investigators have developed several neuropathologic staging systems for Lewy body disorders, but many focus on specific diseases, such as Parkinson’s disease or dementia with Lewy bodies. They thus do not allow the classification of all patients with Lewy body disorders. In addition, the literature contains few data about how well these systems’ stages correlate with clinical and pathologic findings.

The Emergence of the USSLB

Dr. Adler and colleagues proposed the USSLB in research published in Acta Neuropathologica in 2009. Their goal was to enable the classification of patients with Lewy body disorders, regardless of their specific diagnoses. The USSLB includes four stages. Stage I denotes pathology limited to the olfactory bulb. Stage IIa denotes predominantly brainstem involvement. Stage IIb refers to pathology predominantly in the limbic system, rather than the brainstem. Stage III denotes pathology in the brainstem and limbic system. Stage IV represents neocortical pathology.

To examine the correlation between patients’ motor and nonmotor findings, including cognitive measures, and the extent of Lewy-type synucleinopathy, as categorized by the USSLB, Dr. Adler and others examined data from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND). That study includes participants in the Banner Sun Health Research Institute brain and body donation program. Participants undergo annual clinical exams that include movement testing, cognitive testing, sleep and autonomic questionnaires, and a smell test.

Pages

Recommended Reading

PPI use not linked to cognitive decline
MDedge Neurology
Targeting obesity could slow brain aging in psychosis
MDedge Neurology
Anticholinergics’ link to dementia calls for vigilance in elderly
MDedge Neurology
Multisensory Impairment Is Associated With Risk of Dementia
MDedge Neurology
Conference News Roundup—European Society of Cardiology
MDedge Neurology
Transient epileptic amnesia: Rare, treatable, and easy to miss
MDedge Neurology
Brain Stimulation May Enhance Memory
MDedge Neurology
Alzheimer’s Disease Biomarkers, Not Cognition, Will Now Define Disorder
MDedge Neurology
Commentary—A Logical and Modern Approach
MDedge Neurology
Multisensory Impairment Is Associated With Risk of Dementia
MDedge Neurology